BioSpace News Archive

Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule detection assay platform under development.

AIROS Medical, Inc., a designer, manufacturer, and distributor of compression therapy devices, and Fist Assist Devices, LLC (Fist Assist), an innovative medical device company, today announced the launch of an e-commerce website, www.fistassistusa.com, for the sale of the Fist Assist FA-1 compression device.

genOway, a world leader in the field of genetically modified innovative research models, announced that it has granted a non-exclusive CRISPR/Cas9 license to the most important funding institution of biomedical academic research in the United Kingdom.

Paracrine, Inc. announced today that the FDA has granted full approval of its Investigational Device Exemption (IDE) to conduct a pivotal trial titled Scleroderma Treatment with Celution Processed Adipose Derived Regenerative Cells: A Randomized, Double-blind, Placebo-Controlled Study - the “STAR II Trial.”

Eisana Corporation, and Cortex Design, an award-winning engineering design firm focused on medical and life sciences, have solidified a collaborative agreement for the development of Eisana’s first product—an affordable, tech-enabled device to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), today announced data showing that IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system.

Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announces two treatment milestones.

A significant portion of people who contract the SARS-CoV-2 virus – some estimates suggest more than 40 percent – suffer chronic effects known as Post Acute Sequelae of COVID-19 (PASC), commonly referred to as long COVID.

Greetings From The CEO And Staff At HALBERD CORPORATION (OTC Pink: HALB)!

FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson’s Disease.